GlucoTrack Stock Jumps 40% On Strong Clinical Data For Implantable Glucose Monitor

(RTTNews) - GlucoTrack, Inc. (GCTK) surged 40.26 percent to $8.24 on Wednesday following the presentation of positive first-in-human clinical trial results at the American Diabetes Association's 85th Scientific Sessions.

The stock opened sharply higher at $14.74 and has traded between $8.54 and $15.90 so far today on the Nasdaq. Volume spiked to 21.5 million shares, significantly above its average of 81,587. GlucoTrack's 52-week range is $5.16 to $3,756.00.

The company's implantable Continuous Blood Glucose Monitor met all primary and secondary endpoints, achieving a MARD of 7.7 percent, a 99 percent data capture rate, and no serious adverse events.